Adial Pharmaceuticals
ADIL
11 hedge funds and large institutions have $980K invested in Adial Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
22% more funds holding
Funds holding: 9 → 11 (+2)
0% more ownership
Funds ownership: 0.01% → 0.01% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
4% less capital invested
Capital invested by funds: $1.02M → $980K (-$43.8K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RWM
Raffa Wealth Management
Washington,
District of Columbia
|
+$71.3K |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$18.1K |
| 3 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$6.38K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$2.13K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.06K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$18.1K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$3K |
ADIL Hedge Fund Activity: Q3 2019 in Review
11 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q3 2019, worth a combined $980K — down 4.3% from $1.02M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ADIL positions and 2 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Raffa Wealth Management, opening a new position worth an estimated $71.3K. The largest seller was Vanguard Group, cutting an estimated $18.1K.
- 11 institutional investors held Adial Pharmaceuticals (ADIL) as of Q3 2019, up from 9 in Q2 2019.
- Funds reported $980K of Adial Pharmaceuticals stock for Q3 2019, down 4.3% quarter-over-quarter.
- 4 funds opened new Adial Pharmaceuticals positions in Q3 2019 and 2 closed out, a net change of +2 holders.
- The largest Adial Pharmaceuticals buyer in Q3 2019 was Raffa Wealth Management, an estimated $71.3K added.
- The largest Adial Pharmaceuticals seller in Q3 2019 was Vanguard Group, an estimated $18.1K sold.
Based on aggregated 13F filings for Q3 2019.